Psoriatic Arthritis and Psoriasis Treatment Decision Aid (DA)

February 12, 2026 updated by: University of Pennsylvania

Developing a Patient-centered Patient Decision Aid for Psoriasis and/or Psoriatic Arthritis Using Design Thinking.

The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Prior to the interventional study, we will develop a decision aid using design thinking. In this interventional study, we will implement and test a patient-centered decision aid for therapy selection among patients with psoriasis and/or psoriatic arthritis who are starting or switching to a new medication.

Study Type

Interventional

Enrollment (Actual)

37

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Hospital at the University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age 18 years or older
  2. Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist)

  3. Treated at Penn

    In addition to the above, for the observation and implementation phases of the study:

  4. Initiation of a new psoriasis or psoriatic arthritis treatment

    • Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation
    • Patients may be taking other traditional DMARDs.
    • A washout period is not required.

Exclusion Criteria:

  1. Unable to give informed consent
  2. Youth, under the age of 18 years
  3. Patients without psoriasis or psoriatic arthritis

  4. Not being treated at a Penn clinic

    In addition to the above, for the observation and implementation phases of the study:

  5. Not starting or switching to a new medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Decision Aid Testing
Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
Other: Decision Aid
Participants will test decision aid prototypes that are designed to assist them in choosing a medication.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient and provider self-reported perceptions of the decision aid as measured by satisfaction survey
Time Frame: Up to 24 months
Satisfaction survey to rate the decision aid and shared decision-making process
Up to 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of times decision aid was used in consultation for patients switching therapies or starting a new treatment.
Time Frame: Up to 24 months
Rates of of the decision aid use
Up to 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Pennsylvania

Collaborators

Pfizer

Investigators

  • Principal Investigator: Alexis Ogdie-Beatty, MD, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2018

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

October 31, 2018

First Submitted That Met QC Criteria

November 8, 2018

First Posted (Actual)

November 9, 2018

Study Record Updates

Last Update Posted (Actual)

February 17, 2026

Last Update Submitted That Met QC Criteria

February 12, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 831515

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Participant data will be used to create the decision aids which will then be made available to patients, researchers, and medical centers. Physicians and researchers may request de-identified data from the PI and research plans will be reviewed on a case by case basis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on Decision Aid

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe